NUTRIBAND
@ 2/29/24
| Status | Public Micro-cap |
| SCW Listing | 12/2023 |
| Ticker | NTRB |
| Domicile | U.S.A. |
| SCW Type | Save World |
| Industry | Drug Delivery |
| Revenue | Yes |
| 52 Week High | $4.99 |
| 52 Week Low | $1.53 |
| All-Time High (12/27/21) | $10.44 |
| All-Time Low (10/23/23) | $1.53 |
Developer of transdermal pharmaceutical products. Lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology.
Recommended Videos
Discussion with
Nutriband (NTRB) Management
– Jan 6 2024
Nutriband has Potential to be
Hottest stock of 47 year career
– Jan 6 2024
Nutriband Articles
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a...
$25K has Potential for $377M via “Liquid Hyper Growth Strategy”
A Liquid Hyper Growth Strategy (LHGS) has been devised to fully leverage four digital companies having exponential potential. The LHGS has a two-fold purpose: Generate a significant short term cash profit from selling securities which exceeds total amount invested...
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
ORLANDO, FL / ACCESSWIRE / April 1, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announces it has been engaged by and received a first order from Fit For Life Group (FFL), a major...
New Technology Aims to Up the Ante in the Fight Against Opioid Abuse
Millions of people across the world suffer from pain. Chronic discomfort is an unfortunate reality, whether from an accident or serious illness. Luckily, access to medications and alleviation treatments are available. Modern medicine has allowed awful afflictions of...
Nutriband (NTRB) & SaveChangeWorld.com (SCW) Videos
| SCW Produced* | Date | View Link | Duration |
|---|---|---|---|
| Nutriband's year end buy limit price | Dec 28 2024 | https://share.vidyard.com/watch/6fSun2yQ6ikFCBhw6CpDmN | 4:33 |
| Year End Trading Strategy: INVU, AXIL, RVPH, NTRB, HSDT, GRST & AKEMF | Dec 14 2024 | https://share.vidyard.com/watch/pBiQKx3q5PhMDRipHXz56m | 8:12 |
| President of Nutriband (NTRB) Provides Update | Oct 19 2024 | https://share.vidyard.com/watch/TdfggmugBJxebmyKXPsHSf | 10:36 |
| $25K has Potential for $377M via “Liquid Hyper Growth Strategy” | Sep 27 2024 | https://savechangeworld.com/2024/09/27/25k-has-potential-for-377m-via-liquid-hyper-growth-strategy/ | -- |
| Nutriband's Adjusted Price Limits | June 06 2024 | https://share.vidyard.com/watch/6fSun2yQ6ikFCBhw6CpDmN? | 4:14 |
| Updates for NTRB & RVPH | June 15 2024 | https://share.vidyard.com/watch/qegy2jpAoXRu1Huwp3pcFe | 1:20 |
| Updates for SCW's INVU, RVPH, NTRB, AKEMF & Capital Engine | June 08 2024 | https://share.vidyard.com/watch/NZwjtPSce8cCXLqzsBbTUx | 5:15 |
| Nutriband Shares Breaking out! | May 25 2024 | https://share.vidyard.com/watch/GaDJS9uUUnxPzaLVxEDDR9 | 2:27 |
| NTRB shares, technical buy at above $4.95 | May 18 2024 | https://share.vidyard.com/watch/Ej8Jh8eEzvxZiirgyxMvgT | 2:34 |
| With Successful Raise, Nutriband has GREEN light | Apr 20 2024 | https://share.vidyard.com/watch/KYzWPsVgJ89ELHjiZnwShF | 2:31 |
| Nutriband, a Core Markowski Defensive Growth Recommendation | Apr 6 2024 | https://share.vidyard.com/watch/o3xjuMmWYKaxf1kG8sHt4t | 12:10 |
| Significance of Nutriband's 3/27/24 Aversa Regulatory Path Announcement | Apr 6 2024 | https://share.vidyard.com/watch/PwPdcTGAhpE7uQLDurG5CX | 4:16 |
| Nutriband's April Fool's Day Press Release, a BLOCKBUSTER | Apr 6 2024 | https://share.vidyard.com/watch/43Zp5ak8HuuaHtSCVt7r8g | 4:34 |
| Markowski, Chomping at the Bit to Squeeze NTRB Shorts | Apr 6 2024 | https://share.vidyard.com/watch/xiGaEuE8LG9B18MUnbF62C | 14:55 |
| Markowski & NTRB President Melnik on Share Price not Reflecting Significant Announcements | Apr 6 2024 | https://share.vidyard.com/watch/gBcSDiHC6peV5Kz7mQamwe | 29:57 |
| Nutriband's Share Price Breaks Through Resistance | Mar 30 2024 | https://share.vidyard.com/watch/1Xbx1Park17m8iELwPxvtY | 2:29 |
| Discussion with Nutriband (NTRB) Management | Jan 6 2024 | https://share.vidyard.com/watch/s3BXudMTDp6CEC9DRAYaaa | 44:07 |
| Why Timing (macro) is right to Buy & Hold NTRB and other small caps | Jan 6 2024 | https://share.vidyard.com/watch/22A6rsmHRRmQocninQhNcB | 6:29 |
| Nutriband has Potential to be Hottest stock of 47 year career | Jan 6 2024 | https://share.vidyard.com/watch/LfNhVzQpSVWGKbvcQaUqoU | 5:46 |
| NTRB in Position to Leverage Big CDC (Center of Disease Control) Mistake! | Jan 6 2024 | https://share.vidyard.com/watch/sweskSN1rPs3DiFDvJqubL | 7:51 |
| NTRB Projections & Go to Market Strategy | Jan 6 2024 | https://share.vidyard.com/watch/aBosKdbDHKyLYfpmM1Tydk | 13:02 |
| Aversa's Patented Breakthrough Explained | Jan 6 2024 | https://share.vidyard.com/watch/AV5XYhBdWeHQLaMwYASLcR | 7:33 |
| Other Markets for Aversa including ADHD! | Jan 6 2024 | https://share.vidyard.com/watch/GxWaqK91TX2nqQ6F9CKaWD | 4:45 |
| Probability High for FDA to Mandate Aversa | Jan 6 2024 | https://share.vidyard.com/watch/5QyLBjxUmqrR5rmz8kwm7Z | 4:36 |
| NTRB Share Price Analysis & Upside | Jan 6 2024 | https://share.vidyard.com/watch/V8SAbjqaFWYwmnYBco7bBt | 5:57 |
Nutriband (NTRB) & SaveChangeWorld.com (SCW) Videos
Nutriband’s year end buy limit price – Dec 28 2024 – 4:33
https://share.vidyard.com/watch/6fSun2yQ6ikFCBhw6CpDmN
Year End Trading Strategy: INVU, AXIL, RVPH, NTRB, HSDT, GRST & AKEMF – Dec 14 2024 – 8:12
https://share.vidyard.com/watch/pBiQKx3q5PhMDRipHXz56m
President of Nutriband (NTRB) Provides Update – Oct 19 2024 – 10:36
https://share.vidyard.com/watch/6fSun2yQ6ikFCBhw6CpDmN
$25K has Potential for $377M via “Liquid Hyper Growth Strategy” – Sep 27 2024
https://savechangeworld.com/2024/09/27/25k-has-potential-for-377m-via-liquid-hyper-growth-strategy/
Nutriband’s Adjusted Price Limits – July 06 2024 – 4:14
https://share.vidyard.com/watch/6fSun2yQ6ikFCBhw6CpDmN
Updates for NTRB & RVPH – June 08 2024 – 1:20
https://share.vidyard.com/watch/qegy2jpAoXRu1Huwp3pcFe
Updates for SCW’s INVU, RVPH, NTRB, AKEMF & Capital Engine – June 08 2024 – 5:15
https://share.vidyard.com/watch/NZwjtPSce8cCXLqzsBbTUx
Nutriband Shares Breaking out! – May 25 2024 – 2:27
https://share.vidyard.com/watch/GaDJS9uUUnxPzaLVxEDDR9
NTRB shares, technical buy at above $4.95 – May 18 2024 – 2:34
https://share.vidyard.com/watch/Ej8Jh8eEzvxZiirgyxMvgT
With Successful Raise, Nutriband has GREEN light – Apr 20 2024 – 2:39
https://share.vidyard.com/watch/KYzWPsVgJ89ELHjiZnwShF
Nutriband, a Core Markowski Defensive Growth Recommendation – Apr 06 2024– 12:20
https://share.vidyard.com/watch/o3xjuMmWYKaxf1kG8sHt4t
Significance of Nutriband’s 3/27/24 Aversa Regulatory Path Announcement – Apr 6 2024 – 4:16
https://share.vidyard.com/watch/PwPdcTGAhpE7uQLDurG5CX
Nutriband’s April Fool’s Day Press Release, a BLOCKBUSTER – Apr 6 2024 – 4:34
https://share.vidyard.com/watch/43Zp5ak8HuuaHtSCVt7r8g
Markowski, Chomping at the Bit to Squeeze NTRB Shorts – Apr 6 2024 – 14:55
https://share.vidyard.com/watch/xiGaEuE8LG9B18MUnbF62C
Markowski & NTRB President Melnik on Share Price not Reflecting Significant Announcements – Apr 6 2024 – 29:57
https://share.vidyard.com/watch/gBcSDiHC6peV5Kz7mQamwe
Nutriband‘s Share Price Breaks Through Resistance – Mar 30 2024 – 2:29
https://share.vidyard.com/watch/1Xbx1Park17m8iELwPxvtY
Discussion with Nutriband (NTRB) Management – Jan 6 2024 – 44:07
https://share.vidyard.com/
Why Timing (macro) is right to Buy & Hold NTRB and other small caps – Jan 6 2024 – 6:29
https://share.vidyard.com/
Nutriband has Potential to be Hottest stock of 47 year career – Jan 6 2024 – 5:46
https://share.vidyard.com/
NTRB in Position to Leverage Big CDC (Center of Disease Control) Mistake! – Jan 6 2024 – 7:51
https://share.vidyard.com/
NTRB Projections & Go to Market Strategy – Jan 6 2024 – 13:02
https://share.vidyard.com/
Aversa’s Patented Breakthrough Explained – Jan 6 2024 – 7:33
https://share.vidyard.com/
Other Markets for Aversa including ADHD! – Jan 6 2024 – 4:45
https://share.vidyard.com/
Probability High for FDA to Mandate Aversa – Jan 6 2024 – 4:36
https://share.vidyard.com/
NTRB Share Price Analysis & Upside – Jan 6 2024 – 5:57
https://share.vidyard.com/
STOCK
GENERAL INFORMATION:
Source: Nutriband
Innovative Transdermal Technologies and Patient Focused Pharmaceutical products
At Nutriband and their subsidiaries, their core focus is to use innovative drug delivery systems and devices to improve patient outcomes, specifically targeting the Global Opioid epidemic. Fentanyl and other opioid based transdermal medications unfortunately play a role in a significant number of opioid deaths each year with no solution currently available.
Working with their Clinical subsidiary 4P Therapeutics, they have developed a technology called AVERSA which they believe with FDA approval will revolutionize the safety standard for these medications and save countless lives per year.
DEVELOPING PHARMACEUTICAL PRODUCTS
Research & Innovation
Through Nutriband’s Clinical Subsidiary 4P Therapeutics, their Company has capabilities for developing pharmaceutical products from pre-clinical testing to clinical manufacturing and early stage clinical development (Phase I/II).
A key company focus and area of expertise at 4P is in the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery of commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy and therapeutic outcomes associated with these treatments.
Source: Nutriband